The DF/HCC Gl SPORE Career Development Program (CDP) is designed to provide the incentive and structure necessary to attract junior investigators in basic, translational and clinical research into Gl cancer. The overall goal of the CDP is to nurture the success of talented new researchers in Gl cancer. By providing research support and exposure to the Gl SPORE investigators, we hope to promote the independent research careers of junior faculty. Moreover, the SPORE CDP strives to attract minority and female investigators to the field of Gl cancer. The investigators assembled in the DF/HCC Gl SPORE have a substantial record in mentorship of junior faculty working in Gl cancer research. The Gl SPORE CDP has established a formal process for the identification, selection, and mentoring of individuals pursing careers in the study of basic, clinical, and population science-based aspects of Gl cancer. The CDP Governance and Review Committee, led by outstanding senior mentors across BWH, MGH, DFCI, and BIDMC, direct a program that ensures optimal selection, support, and oversight of the Gl SPORE CDP. Over the past funding cycle, the CDP has selected, funded, and mentored 15 talented young investigators in Gl cancer who have made exceptional career development as well as substantial contributions to the field of Gl cancer.
The Specific Aims of the Career Development Program are: 1. Establish a system to identify promising young investigators seel

Public Health Relevance

Career development of young faculty is vital to the continued progress in reducing the burden of Gl cancer. The DF/HCC Gl SPORE Career Development Program (CDP) is designed to provide the incentive and structure necessary to attract junior investigators in basic, translational and clinical research to focus on key issues in Gl cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA127003-07
Application #
8933248
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Program Officer
Agarwal, Rajeev K
Project Start
2007-04-01
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
7
Fiscal Year
2014
Total Cost
$100,267
Indirect Cost
$60,788
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Strickler, John H; Loree, Jonathan M; Ahronian, Leanne G et al. (2018) Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discov 8:164-173
Khalaf, Natalia; Yuan, Chen; Hamada, Tsuyoshi et al. (2018) Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies. Gastroenterology 154:1380-1390.e5
Hamada, Tsuyoshi; Liu, Li; Nowak, Jonathan A et al. (2018) Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour. Eur J Cancer 103:98-107
Qian, Zhi Rong; Rubinson, Douglas A; Nowak, Jonathan A et al. (2018) Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol 4:e173420
Nevo, Daniel; Nishihara, Reiko; Ogino, Shuji et al. (2018) The competing risks Cox model with auxiliary case covariates under weaker missing-at-random cause of failure. Lifetime Data Anal 24:425-442
Ma, Siyuan; Ogino, Shuji; Parsana, Princy et al. (2018) Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis. Genome Biol 19:142
Guercio, Brendan J; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One 13:e0199244
Neumeyer, Sonja; Banbury, Barbara L; Arndt, Volker et al. (2018) Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer. Br J Cancer 118:1639-1647
Aguirre, Andrew J; Nowak, Jonathan A; Camarda, Nicholas D et al. (2018) Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov 8:1096-1111
Hill, Margaret A; Alexander, William B; Guo, Bing et al. (2018) Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma. Cancer Res 78:4445-4451

Showing the most recent 10 out of 590 publications